Munive LMR, Simón DJI, González SR, Suárez BME

Language: Spanish
References: 11
Page: 100-104
PDF size: 73.30 Kb.

ABSTRACT

The detection of antinuclear antibodies is an important tool in the diagnosis of several connective tissue diseases. The standard method for its determination is the indirect immunofluorescence analysis, whose disadvantages like subjectivity and complexity have caused the generation of new tests; one of them is the chemiluminescent immunoassay, which is an automated technique with high sensitivity. The aim of the present work was to evaluate chemiluminescent immunoassay and compare them with indirect immunofluorescence for the detection of antinuclear antibodies. We did a descriptive and cross-sectional study in the ABC Medical Center, between november 2006 to february 2008. We analyzed 208 samples, obtaining the following results: 95% sensitivity, 59% specificity, 67% positive predictive value and 94% negative predictive value. Due to the high sensibility the chemiluminescent immunoassay is an attractive alternative as an screening method for antinuclear antibodies, whereas to the positive results it is recommended to confirm titles and patterns using indirect immunofluorescence.

REFERENCES

1. Hoffman IE, Peene I, Veys EM, De Keyser F. Detection of specific antinuclear reactivities in patients with negative antinuclear antibody immunofluorescence screening test. Clin Chem 2002; 48 (12): 2171-2176.

2. Fenger M, Wiik A, Hoier-Madsen M, Lykkegaard JJ, Rozenfeld T et al. Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence analysis. Clin Chem 2004; 50 (11): 2141-2147.

3. Ulvestad E, Kanestrom A, Madland TM, Thomassen E, Haga HJ et al. Evaluation of diagnostic test for antinuclear antibodies in rheumatological practice. Scand J Immunol 2000; 52: 309-315.

4. Tozzoli R, Bizzaro N, Tonutti E, Villalta D, Bassetti D et al. Guidelines for the laboratory use of autoantibody test in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 2002; 117 (2): 316-324.

5. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-Based guidelines for the use of immunologic test: Antinuclear antibody testing. Arthritis Rheum 2002; 47 (4): 434-444.

6. Gniewek RA, Stites DP, McHugh MT, Hilton JF, Nakagawa M. Comparison of antinuclear antibody testing methods: Immunofluorescence assay versus enzyme immunoassay. Clin Diagn Lab Immunol 1997; 4 (2): 185-188.

7. Hayashi N, Kawamoto T, Mukai M, Morinobu A, Koshiba M et al. Detection of antinuclear antibodies by use of an enzyme immunoassay with nuclear HEp-2 cell extract and recombinant antigens: Comparison with immunofluorescence assay in 307 patients. Clin Chem 2001; 47 (9): 1649-1659.

8. Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D et al. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. Arthritis Rheumatism 1999; 42 (3); 455-464.

9. Kern P, Kron M, Hiesche K. Measurement of antinuclear antibodies: Assessment of different test systems. Clin Diagn Lab Immunol 2000; 7 (1): 72-78.

10. García-Campaña AM, Baeyens WRG, Zhang X, Alés F, Gámiz L. Quimioluminiscencia: Una interesante alternativa para la detección analítica en sistemas de flujo. Ars Pharmaceutica 2001; 42 (1): 81-107.

11. Ghillani P, Rouquette AM, Desgruelles C, Hauguel N, Le Pendeven et al. Evaluation of the LIAISON ANA screen assay for antinuclear antibody testing in autoimmune diseases. Ann N Y Acad Sci 2007; 1109: 407-413.